Importantly, while SNRPD1 over-expression is prognostic of poor RFS for ER-HER2- (corresponding to TNBC) and ER+HER2- (mostly referring to luminal A) tumors as well as suggests favorable RFS outcome for ER-HER2+ tumors (i.e., HER2+ breast cancers), high level of SNRPE conveys no prognostic value for none of these breast cancer subtypes (Fig. 2). This evidence concerns the gene SNRPD1 and breast cancer.